Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...
In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven ...
This approach offers an enhanced therapeutic effect with minimal systemic toxicity, addressing one of oncology’s ...
Based on the response data, coupled with the supportive IFN- <GAMMA> biomarker data, Pliant plans to accelerate the development of PLN-101095 with the initiation of a Phase 1b indication expansion ...
PIN-5018 achieves complete response in ACC PDX models Expansion planned into mCRPC, colorectal cancer, and other rare tumours ...
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting ...
Cancer remains a major global health challenge, accounting for millions of deaths each year despite rapid advances in diagnostics and therapeutics. The ...
GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging ...
Obesity is the excessive or abnormal accumulation of fat or adipose tissue in the body that impairs health via its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback